Cantargia AB Patents

Patent portfolio assigned to Cantargia AB (verified via public assignee records). Estimated patent count: 300. Clinical-stage biotech developing anti-IL1RAP antibody nadunolimab (CAN04) for cancer/inflammation (Lund). Competitors from sourced company profile; the IL1RAP niche is specialized so competitor mapping is approximate. Patents confirmed via Google Patents (assignee Cantargia Ab); count is an estimate inflated by family members.